List view / Grid view
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
Drug discovery company, TauGen, has filed a US patent application for a new series of drug candidates targeting endoplasmic reticulum (ER) stress – a key factor in secondary brain injury following traumatic brain injury (TBI).
A team has demonstrated that their bioinformatics approach, PlasmidHawk, can analyse DNA sequences to identify the source of engineered plasmids.
To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen.
Last year, the European Patent Office (EPO) saw the number of patents filed in the pharmaceutical and biotechnology sectors rise for the third year in a row.
Researchers have applied for a patent for their innovative cantilever and vibrating plate technique which they say could increase the speed of atomic force microscopy on fragile samples.
Arguments filed in opposition to a patent for foundation CRISPR-Cas9 intellectual property have been broadly rejected by the European Patents Office.
The patent office has declared an interference between 10 University of California (UC) patent applications.
When important and valuable patents expire, some rejoice and some dismay. Usually, after 20 years of protection, a masterpiece becomes available to all to reproduce, at the loss of the former patent owner...
2 March 2016 | By Victoria White
The US Patent 9,273,283 is the second patent of Celyad allogeneic intellectual property portfolio that is awarded by the USPTO...
All new drugs rely, to a greater or lesser extent, on pre-existing research and development. Much of this pre-existing research will have resulted in patented methods and products. A major challenge for all researchers is therefore to develop new drugs which do not infringe other company’s patents.
11 May 2015 | By Victoria White
US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
8 April 2015 | By Victoria White
Cardio3 has received a Notice of Allowance from the USPTO for a patent application covering TCR-deficient T-Cells which are engineered to express a CAR...
18 March 2015 | By Victoria White
TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
11 February 2015 | By Cancer-Code Corporation
Another foundation patent in the burgeoning field of bioelectronic medicine, specifically for treating cancer patients...
